Piaoyang Sun

This inventor holds 42 USPTO granted patents and 5 published patent applications, plus 9 CIPO patents and 24 EPO patents, primarily in Antibody Therapeutics. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Medivir Ab. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Piaoyang Sun. Retrieved from https://idiyas.com/inventor/piaoyang-sun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 9 (Patent Applications = 7)

EPO Patents = 24 (Patent Applications = 30)

Average Co-Inventor Count = 4.7

ph-index = 6

Forward Citations = 71(Granted Patents)

Location History:

Shanghai, CN (2013)
Lianyungang, CN (2011 - 2017)
Jiangsu, CN (2012 - 2024)

Company Filing History:

35 out of 159

Jiangsu Hengrui Medicine Company Ltd.

patents

25 out of 100

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

patents

5. 1 out of 10

Jiangsu Hansoh Pharmaceutical Co., Ltd.

patents

6. 1 out of 1

Jiangsu Hengrui Co., Ltd.

patent

7. 1 out of 1

Suzhou Suncediabiopharmaeuticals Co., Ltd.

patent

8. 1 out of 1

Unitris Biopharma Co., Ltd.

patent

9. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

Antibody

PD-L1

LAG-3

IL-15

VEGFR Inhibitor

PARP Inhibitor

Tyrosine Kinase Inhibitor

CDK4/6 Inhibitor

PCSK9

Pharmaceutical Applications

Cancer Treatment

Drug Development

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11981733 - LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof (2024-05-14),

2. 11780923 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2023-10-10),

3. 11717559 - Interleukin 15 protein complex and use thereof (2023-08-08),

4. 11155617 - LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof (2021-10-26),

5. 11000518 - Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer (2021-05-11),

6. 10905743 - Interleukin 15 protein complex (2021-02-02),

7. 10857146 - Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor (2020-12-08),

8. 10815304 - PD-L1 antibody, antigen-binding fragment thereof and medical application thereof (2020-10-27),

9. 10793643 - PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof (2020-10-06),

10. 10786567 - Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine (2020-09-29),

11. 10759788 - Pharmaceutical uses of pyridine carboxamide derivatives (2020-09-01),

12. 10633388 - Pyrazolopyrimidone derivatives and methods of use thereof (2020-04-28),

13. 10442794 - Processes for preparing pyridine carboxamide derivatives (2019-10-15),

14. 10442793 - Oxa spiro derivative, preparation method therefor, and applications thereof in medicines (2019-10-15),

15. 10398689 - Benzopiperidine derivative, preparation method thereof and medical use thereof (2019-09-03),

Title: **The Innovative Mind of Piaoyang Sun**

Introduction

Piaoyang Sun, an accomplished inventor based in Jiangsu, China, has made significant contributions to the field of biotechnology, particularly in cancer treatment. With an impressive portfolio of 42 patents, he has become a notable figure in the development of therapeutic antibodies.

Latest Patents

Among his latest inventions, Piaoyang Sun has developed two groundbreaking patents:

1. **LAG-3 Antibody, Antigen-Binding Fragment Thereof, and Pharmaceutical Application Thereof**: This innovative work includes a LAG-3 antibody and various forms, including chimeric and humanized antibodies. These formulations exhibit potential as antineoplastic drugs, especially emphasizing the application of a humanized LAG-3 antibody in treating diseases involving immune cells.

2. **PD-L1 Antibody, Antigen-Binding Fragment Thereof and Medical Application Thereof**: This patent focuses on a PD-L1 antibody and its antigen-binding fragments. It also includes chimeric and humanized antibodies based on the PD-L1 structure. These developments are directed toward anti-cancer treatments, highlighting the humanized PD-L1 antibody's application in preparing medicaments for disorders mediated by PD-L1.

Career Highlights

Piaoyang Sun’s career is highlighted by his work at prominent companies such as Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His expertise and innovative approach have placed him in a leading position in the pharmaceutical industry, especially in the research for cancer therapies.

Collaborations

Piaoyang has collaborated with esteemed colleagues, including Lianshan Zhang and Qing Dong, demonstrating his commitment to teamwork and collective innovation in the field of medical research.

Conclusion

Piaoyang Sun is a prominent inventor driving advancements in oncology through his inventive spirit and extensive patent portfolio. His contributions, particularly in antibody therapies, highlight his role in the quest for innovative cancer treatments that can significantly enhance patient outcomes. The impact of his work continues to resonate within the scientific community, paving the way for future discoveries.

Profile summary based on public USPTO records.